DAWN WADE: Open Payments
NPI 1982142253 · JOPLIN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,063 in 61 payments from 10 companies in 2025. Trend: 2023 $322 · 2024 $937 · 2025 $1,063
Food & beverage: $1,063
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $390 |
| Alkermes, Inc. | 14 | $292 |
| ABBVIE INC. | 15 | $156 |
| HARMONY BIOSCIENCES LLC | 2 | $64 |
| Janssen Pharmaceuticals, Inc | 3 | $52 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Dexcom, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Grifols USA, LLC | 1 | $14 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, WAKIX, SPRAVATO, Qelbree, Dexcom G6 Transmitter, REXULTI.
Industry payments across MO — which companies pay providers there.
